Anand Padmanabhan MD, PhD
President & Chief Science Officer
Dr. Anand Padmanabhan, MD PhD is a Laboratory Medicine and Transfusion Medicine/Apheresis-trained physician. He received his medical degree from Thanjavur Medical College (India), PhD in Biochemistry from Brown University, and trained in leading programs in Laboratory Medicine (College of Physicians and Surgeons of Columbia University) and Transfusion Medicine/Apheresis (University of Pittsburgh Medical Center). He served on the faculty of the Blood Research Institute of the BloodCenter of Wisconsin for 9+ years and is currently a physician-scientist at the Mayo Clinic in Rochester, MN. He is funded by the NIH to study Heparin induced Thrombocytopenia and thrombosis (HIT), a major cause of morbidity (30% thrombosis rate) and mortality (10%) in heparin-treated patients. Dr. Padmanabhan's interests include HIT epidemiology, pathogenesis, diagnosis and treatment and he has published in these areas in leading journals such as Blood, Chest and Lancet Haematology.
PhD, MBA, JD
CEO & General Counsel
Dr. Sem is also Dean and Professor of Business, Professor of Pharmaceutical Sciences and Director of Technology Transfer at Concordia University Wisconsin. He also serves on the editorial board of PLoS One Life Sciences, the Boards of Directors for the BBB and for Ozaukee County Economic Development Corp. Dr. Sem has over 20 years of experience in drug discovery and development, and has over 60 papers and 10 issued patents. He co-founded two drug discovery and development companies (Triad and AviMed) and one social venture (Bridge to Cures) before Retham. He served as VP for Biophysics at Triad Therapeutics, where he developed a platform technology for designing focused combinatorial libraries targeting kinases and dehydrogenases. He co-founded Triad Therapeutics based on technology he developed and patented, and he assisted in securing two rounds of venture financing, totaling over $40 million. Triad was voted one of the top 10 biotech startups in the U.S. in 2001 by Drug Discovery Today, and licensed kinase drug leads to Novartis for up to $60 million. Dr. Sem received his B.S. in Chemistry from UW-Milwaukee, his Ph.D. from UW-Madison in Biochemistry and his MBA and JD degrees from Marquette University.
Director, Research & Development
Curtis received his Bachelor's of Science in Chemistry from the University of Wisconsin-Milwaukee. He had key collaborations with Dr. Padmanabhan on key studies on HIT pathophysiology from 2012-2019, while at the BloodCenter of Wisconsin. Curtis has authored numerous papers in high impact journals on HIT diagnosis, treatment and pathogenesis. He is intimately familiar with the technical and scientific aspects of HITDx development.
Mark focuses his practice on the drafting and prosecution of chemical, biochemical, and pharmaceutical patent applications and on patentability and infringement opinions — he has drafted and prosecuted portfolios of multiple patents involving platelet diagnostics, DNA, siRNA, therapeutic particles and proteins. He was the early stage patent counsel for Panvera, Mirus Bio and GTI Diagnostics, all of which began as startups and eventually sold their technology to multinational companies.